Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD‐L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer

BACKGROUND: We examined the current biomarker landscape in breast cancer when programmed death‐ligand 1 (PD‐L1) testing is integrated with comprehensive genomic profiling (CGP). MATERIAL AND METHODS: We analyzed data from samples of 312 consecutive patients with breast carcinoma tested with both CGP...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Huang, Richard S.P., Li, Xinyan, Haberberger, James, Sokol, Ethan, Severson, Eric, Duncan, Daniel L., Hemmerich, Amanda, Edgerly, Claire, Williams, Erik, Elvin, Julia, Vergilio, Jo‐Anne, Killian, Jonathan Keith, Lin, Douglas, Hiemenz, Matthew, Xiao, Jinpeng, McEwan, Deborah, Holmes, Oliver, Danziger, Natalie, Erlich, Rachel, Frampton, Garrett, Cohen, Michael B., McGregor, Kimberly, Reddy, Prasanth, Cardeiro, Dawn, Anhorn, Rachel, Venstrom, Jeffrey, Alexander, Brian, Brown, Charlotte, Pusztai, Lajos, Ross, Jeffrey S., Ramkissoon, Shakti H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2020
Konular:
Cancer Diagnostics and Molecular Pathology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648336/
https://ncbi.nlm.nih.gov/pubmed/32869930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0449
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller